Using Benefit-Risk Measure to Evaluate Alzheimer's Disease Biomarkers: A Collapsing Net Benefit Approach
Document Type
Presentation
Presentation Date
11-7-2022
Abstract or Description
Clinicians may be skeptical of using accuracy measures alone to compare diagnostic tests or biomarkers. In clinical settings, diagnostic test accuracy is usually assessed using classification accuracy or predictive values. The drawback of these metrics is that one test may have higher sensitivity but worse specificity than another. Another method is to compare tests or biomarkers using a benefit-risk measure, which entails quantifying test benefits and clinical consequences of diagnostic errors by putting benefits and harms on the same scale. As a result, weighing the benefits and risks of diagnostic testing necessitates considering both the test's accuracy and the clinical context. For a clinical condition, diagnostic tests are commonly classified into positive and negative categories (diseased or non-diseased). Some diseases, such as Alzheimer's, have more than two stages. The benefit to cost values may fluctuate depending on the stage of the disease. This study demonstrate the application of the net benefit approach to evaluating biomarkers for the diagnosis of Alzheimer's disease (AD) based on a clinical performance study and external data on clinical effects. As a result, we present a diagnostic yield table for AD, a multi-stage clinical condition. Consequently, we develop a decision theory based on net benefit for analyzing biomarkers, which provides additional interpretation for rule-in or rule-out clinical demands, as well as the negative repercussions of superfluous workup.
Sponsorship/Conference/Institution
American Public Health Association (APHA) Annual Conference
Location
Boston, MA
Recommended Citation
Ahmeda, Ferdous, Hani W. Samawi.
2022.
"Using Benefit-Risk Measure to Evaluate Alzheimer's Disease Biomarkers: A Collapsing Net Benefit Approach."
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Presentations.
Presentation 298.
https://digitalcommons.georgiasouthern.edu/bee-facpres/298
Additional Information
Georgia Southern University faculty member, Hani Samawi co-presented Using Benefit-Risk Measure to Evaluate Alzheimer's Disease Biomarkers: A Collapsing Net Benefit Approach in the American Public Health Association (APHA) Annual Conference, November 2022.